Mirvetuximab soravtansine clinical trials
Also written IMGN853 and Elahere.
Its developmentBy 5 companies, company by company15 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses mirvetuximab soravtansine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mirvetuximab soravtansine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Nov 2022 · ELAHERE · BLA 761310 (FDA, Drugs@FDA)
- European Union
- 14 Nov 2024 · Elahere · EMEA/H/C/005036 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 12
AbbVie (7) · ImmunoGen, Inc. (4) · Takeda (1) · Dana-Farber Cancer Institute (1) · AGO Research GmbH (1) · City of Hope Medical Center (1) · Ohio State University Comprehensive Cancer Center (1) · Pfizer (1)
Often tested with
Tested in the same studies.
Bevacizumab (2) · Carboplatin (2) · Suvemcitug (2) · Rucaparib (1) · Influenza Vaccines (1) · Paclitaxel (1) · Liposomal doxorubicin (1) · Doxorubicin (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Mirvetuximab soravtansine is the comparator. A study of two new drugs counts under both.
- 1Bevacizumab · Eli Lilly and Company · next primary completion Nov 2028
- 1Torvutatug samrotecan · AstraZeneca · next primary completion Nov 2028
Reaching primary completion within a year · 5, 1 in phase 3
Studies that test mirvetuximab soravtansine, phase 3 first.
- Apr 2027Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerPhase 3 · AbbVie
- Nov 2026Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerPhase 2 · AbbVie
- Jun 2027Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerPhase 2 · Peking University Third Hospital
- Jul 2027Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal CancerPhase 2 · University of Alabama at Birmingham
- Sep 2027Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerPhase 2 · Fudan University
Studies
Open first, then newest update. How each study uses mirvetuximab soravtansine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian CancerNot yet recruitingPhase 2Tongji HospitalNCT07934121Written as Mirvetuximab Soravtansine
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingPhase 2AbbVieNCT06890338Written as Mirvetuximab Soravtansine
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerRecruitingPhase 2AbbVieNCT07059845Written as Mirvetuximab Soravtansine
- A Study of PHST001 in Advanced Solid TumorsRecruitingPhase 1Pheast TherapeuticsNCT06840886Written as Mirvetuximab Soravtansine
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Mirvetuximab soravtansine (MIRV)
- Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingPhase 2Peking University Third HospitalNCT07741630Written as Mirvetuximab soravtansine
- Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 2University of Alabama at BirminghamNCT04606914Written as mirvetuximab soravtansine (MIRV; IMGN853)
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingPhase 2University of Colorado, DenverNCT05887609Written as Mirvetuximab Soravtansine-gynx
- Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial CancerRecruitingPhase 2Alessandro SantinNCT03832361Written as IMGN853
- A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab SoravtansineRecruitingPhase 2AbbVieNCT06682988Written as Mirvetuximab Soravtansine
- Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast CancerCompletedPhase 1City of Hope Medical CenterNCT02996825Written as Mirvetuximab Soravtansine
- A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid TumorsActive, not recruitingPhase 1/2TakedaNCT06390995Written as TAK-853
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerActive, not recruitingPhase 3AbbVieNCT05445778Written as Mirvetuximab soravtansine plus Bevacizumab
- A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)Active, not recruitingPhase 2Dana-Farber Cancer InstituteNCT03835819Written as IMGN853
- Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian CancerActive, not recruitingPhase 2AGO Research GmbHNCT04274426Written as Mirvetuximab Soravtansine
- Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersCompletedPhase 2AbbVieNCT05041257Written as Mirvetuximab soravtansine
- Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerActive, not recruitingPhase 2AbbVieNCT05456685Written as Mirvetuximab soravtansine
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) ExpressionCompletedPhase 3AbbVieNCT04209855Written as Mirvetuximab Soravtansine
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedPhase 1Ohio State University Comprehensive Cancer CenterNCT03552471Written as Mirvetuximab Soravtansine
- A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionCompletedPhase 3ImmunoGen, Inc.NCT04296890Written as Mirvetuximab Soravtansine
See all 28 studies that test mirvetuximab soravtansine →
Given beside what is tested · 1 — mirvetuximab soravtansine is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with mirvetuximab soravtansine
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingPhase 3Eli Lilly and CompanyNCT07213804Written as MIRV
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerRecruitingPhase 3AstraZenecaNCT07218809Written as Mirvetuximab Soravtansine (MIRV)
What changed recently
From the registry's own updates since Oct 19, 2026.
Newly registered1
- MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian CancerNov 12, 2026NCT07934121
Codes
What other systems call mirvetuximab soravtansine · ClinicalTrials.gg INT000444
- MeSH (NLM) C000607289mirvetuximab soravtansineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 98DE7VN88DMIRVETUXIMAB SORAVTANSINEConfirmed FDA, NLM, Wikidata
- RxNorm 2621548One source FDA
- Wikidata Q115285803mirvetuximab soravtansineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102566Mirvetuximab SoravtansineOne source FDA
- DrugBank DB12489One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607289 | mirvetuximab soravtansine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 98DE7VN88D | MIRVETUXIMAB SORAVTANSINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2621548 | — | One source FDA |
| Wikidata | Q115285803 | mirvetuximab soravtansine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102566 | Mirvetuximab Soravtansine | One source FDA |
| DrugBank | DB12489 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.